drugset / Trial / NCT02295774

Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA

NCT02295774

Phase 2 Completed 10 enrolled Cosmo Technologies Ltd
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Single Centre, open label assignment phase II clinical study. To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to endoscopy on double stranded DNA breaks in colonic biopsy samples assessed by histone gamma H2AX analysis, compared to control biopsies.

Timeline

Start
2013-02
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylene Blue Diagnostic / imaging agent 200 mg Oral

Indications